Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Article Oncology

Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases

Akihiko Ichida et al.

Summary: Lenvatinib may be effective and safe for the treatment of unresectable HCC recurrence after liver transplantation, resulting in relief for patients and improved survival rates.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study

Margherita Rimini et al.

Summary: Lenvatinib showed better performance compared to Sorafenib in a real-world setting, with more research needed to validate predictor factors for Lenvatinib response over Sorafenib.

HEPATOLOGY RESEARCH (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea

Myung Ji Goh et al.

Summary: Lenvatinib therapy demonstrated favorable efficacy and safety in real-world practice, with an objective response rate of 18.9% and a disease control rate of 75.7% based on mRECIST criteria. Common adverse events included diarrhea, hand-foot skin rash, abdominal pain, hypertension, and anorexia.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

Ilario Giovanni Rapposelli et al.

Summary: The occurrence of arterial hypertension G >= 2 predicts longer survival, while decreased appetite G >= 2 predicts a poor prognosis in HCC patients treated with lenvatinib. Careful management of adverse events is necessary to improve patients' quality of life and optimize treatment outcomes.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study

Yen-Yang Chen et al.

Summary: This study enrolled 10 HCC patients who received lenvatinib after liver transplantation, showing a 20% partial response rate and 70% disease control rate. Adverse events were mainly grade 1-2 and well tolerated. There was no significant difference in survival or adverse events compared to HCC patients without liver transplantation who underwent lenvatinib treatment.

CANCERS (2021)

添加到收藏夹

Article Oncology

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study

Kaoru Tsuchiya et al.

Summary: The first-line systemic therapy for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab therapy, and lenvatinib has shown high response rates in real-world practice for unresectable HCC patients in Japan. Pretreatment factors like ALBI score, AFP levels, and major vascular invasion play crucial roles in treatment strategy decisions for these patients.

CANCERS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis

Zhao Li et al.

Summary: This study found that in patients with HCC recurrence after LT, those treated with sorafenib achieved a 1-year survival rate of 56.8%, with a median OS of 12.8 months. Factors such as male gender, TTP, duration of sorafenib treatment, fatigue, and partial response were associated with a better 1-year survival rate. Sorafenib showed a significant survival benefit in patients with untreatable post-LT HCC recurrence compared to best supportive care.

TURKISH JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Immunology